ClinicalTrials.gg
RecruitingNCT06387069Updated Aug 14, 2025

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

A Phase 3 interventional study of HMPL-306 Regimen and Salvage Chemotherapy Regimen in Acute Myeloid Leukemia, sponsored by Hutchmed. Recruiting at 53 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Hutchmed · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
23rd of 433
316 · median 50
Started
2024
with 67 others
Phase 3
54 of 473
25 open now
Primary completion
2028-12
later than 257 of 288 live
Registered
305th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 23rd largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 54 in phase 3, reaches primary completion later than 257 of the 288 other live ones, and was the 305th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.

Read the detailed description

Study Overview This is a multicenter, randomized, open-label, phase III clinical study to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with IDH1- and IDH2-mutated R/R AML (RAPHAEL).

The study is open-label, and all patients will be screened centrally to determine their IDH mutation status, and based on the screening results, the patients will be assigned to the corresponding IDH1 and IDH2 cohorts of this registration study. Patients with both IDH1 and IDH2 mutations be assigned to the IDH2 cohort. The study consists of divided into two cohorts. Patients with R/R AML harboring IDH1-R132 mutation will be included in Cohort 1, and patients with R/R AML harboring IDH2-R140, R172 mutations will be included in Cohort 2. The two cohorts will be designed independently, analyzed separately, and subjected to statistical hypothesis testing separately. Patients in both cohorts will be randomly assigned according to the central randomization system (IWRS) in a 1:1 ratio into the experimental group and the control group. Patients in the experimental group will receive HMPL-306 monotherapy at the following dose: 250 mg once daily (QD) (first cycle, C1) + 150 mg QD [starting from the second cycle (C2)]; patients in the control group will receive salvage chemotherapy (1 of 4), including 4 different treatment regimens: Two intensive regimens (EA± Mitox regimen and FLAG ± Ida regimen) and two non-intensive regimens (azacitidine and LoDAC). Prior to randomization, the investigator will pre-select a salvage chemotherapy regimen based on the patient's condition, and randomization will be stratified according to patients' response to prior first-line therapy (relapse within 6 months after allogeneic HSCT, relapse after 6 months after allogeneic HSCT, primary refractory without HSCT, relapse within 6 months after achieving CR/CRh without HSCT, or relapse after 6 months after achieving CR/CRh without HSCT) and the intensity of the pre-selected chemotherapy regimen (intensive chemotherapy or weak chemotherapy).

After the patients sign the pre-screening informed consent form (ICF), pre-screening (genetic testing) will be performed to determine IDH mutation status for subsequent enrollment cohort, and if a patient wants to know about RAS or FLT3 mutation status, local testing can be used to clarify the latest RAS or FLT3 hotspot mutation. Patients who meet the inclusion criteria of this study will be randomized to the experimental group or the control group to receive treatment in 28-day cycles until one of the following conditions occurs: Treatment failure [refer to the Guidelines for Clinical Development of New Drugs for Acute Myeloid Leukemia issued by the Center for Drug Evaluation (CDE)]. The definition of "treatment failure" is recommended as: Treatment failure occurs when CR or CRh/CRi is not achieved after 2 cycles of treatment per protocol using the regimens for the intensive chemotherapy group. When using the regimens for the weak chemotherapy group and the experimental group, treatment failure occurs if CR or CRh/CRi is not achieved after 4 cycles of treatment, i.e., disease progression/relapse, death, unacceptable toxicity, receiving new anti-tumor therapy, judgment by the investigator that the patient no longer obtains clinical benefit from treatment, withdrawal from the study by the patient or his/her legally acceptable representative, loss to follow-up, or end of the study occurs, whichever occurs first (The treatment duration of EA±Mitox regimen and FLAG±Ida regimen in the chemotherapy group will be adjusted according to the actual medication, and a maximum of two treatment cycles will be used).

Crossover is not allowed for patients with progressive disease in the control group and the experimental group, and patients in the control group will not be allowed to crossover to other salvage regimens.

The information on treatment groups is as follows (same for both cohorts):

The experimental group: Patients treated with HMPL-306 monotherapy:

- The dose of HMPL-306 is 250 mg QD (C1) + 150 mg QD (starting from C2), continuous, PO, in 28-day treatment cycles.

The control group: Patients treated with one of the following regimens, and the regimen will be determined by the investigator on a case-by-case basis:

  • EA±Mitox regimen: Etoposide Injection 100 mg/m2, Cytarabine Injection 100-150 mg/m2, and Mitoxantrone Injection 8 mg/m2, QD, intravenous (IV) administration for 5 consecutive days (Days 1-5). (In the case that Mitoxantrone Injection is not accessible, a regimen containing mitoxantrone liposome can be used, specifically: Mitoxantrone liposome + cytarabine + etoposide regimen: Mitoxantrone liposome 24-32 mg/m2, Day 1; Cytarabine 100-200 mg/m2, Day 1 to Day 7; and Etoposide 100 mg/m2, Days 1-5). The regimen can be used with or without mitoxantrone, which can be determined by the investigator based on the actual condition of the patient.
  • FLAG±Ida regimen: G-CSF Injection 300 mcg/m2, QD subcutaneous administration for 5 consecutive days (Days 1-5); Fludarabine Injection 30 mg/m2, QD IV for 5 consecutive days (Days 2-6); Cytarabine Injection 1000-2000 mg/m2, QD IV for 5 consecutive days (Days 2-6); and Idarubicin Injection 10 mg/m2, QD IV for 3 consecutive days (Days 2-4). This regimen can be used with or without Ida, which can be determined by the investigator based on the actual condition of the patient. After the end of chemotherapy administration, the investigator will determine whether it is necessary to continue the administration of G-CSF, and if necessary, retreatment with G-CSF is allowed until absolute neutrophil count (ANC) > 0.5x109/L.
  • LoDAC: Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10).
  • Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7).

Study Period:

The study includes pre-screening period, screening period, treatment period and follow-up period [including end of treatment (EOT) follow-up, safety observation follow-up, EFS follow-up, and OS follow-up].

The pre-screening period is defined as the period from signing the pre-screening ICF to obtaining the IDH1 and IDH2 mutation testing reports. For patients without previous IDH1 or IDH2 testing reported, specimens should be sent to the central laboratory for IDH1 and IDH2 mutation testing and other companion gene testing after signing the pre-screening ICF and prior to screening. Patients with a previously reported positive IDH1 and/or IDH2 mutation test may proceed directly to screening without pre-screening if approved by the investigator. The results confirmed by the central laboratory are required for enrollment.

The screening period is defined as the period from signing the main screening ICF to Cycle 1 Day 1 pre-dose.

Treatment period is defined as the period from the first dose to EOT. EOT Follow-up: Patients with EOT need to return to the site for EOT follow-up within 1-7 days after discontinuing treatment, or before starting other anti-tumor therapy, whichever occurs first.

Safety Observation Follow-up: Patients with EOT need to return to the site for Safety Observation Follow-up within 30 (±7) days after the last dose of study drug treatment or before starting other anti-tumor therapy, whichever occurs first.

EFS Follow-up: Patients with EOT (except for EOT due to disease progression/relapse) will be advised to remain in the study for EFS follow-up, and patients without medication after randomization will also be advised for EFS follow-up, from the day of entering EFS follow-up, and then every 8 weeks until disease progression/relapse, death, withdrawal by the patient or his/her legally acceptable representative, patient lost to follow-up, or end of study, whichever occurs first. Subsequent new transplant conditioning regimens or new anti-tumor treatment regimens will be documented during EFS follow-up.

OS Follow-up: Patients who have been randomized and have completed EFS follow-up (and who have EOT due to disease progression/relapse) will receive OS follow-up every 8 weeks from the date they enter OS follow-up until death, withdrawal by the patient and his/her legally acceptable representative, loss to follow-up, or end of study, whichever occurs first. If a patient withdraws from treatment and not from the entire study, EFS and OS data collection will be continued.

End of Study Inconsistent time of end of study is allowed between the two cohorts. The end of study for each cohort is defined as the time when the target number of OS events for the final analysis is reached in the cohort. The actual duration of study for each cohort will depend on the actual enrollment rate, dropout rate, and the length of median OS in each group.

Efficacy Assessment(s) Efficacy evaluation will be based on modified 2022 European Leukemia Net (ELN) criteria. Efficacy assessment will be performed once for each of the first 6 cycles of study drug treatment (i.e., C2D1, C3D1, C4D1, C5D1, C6D1, C7D1) and every 2 cycles after 6 cycles of treatment (i.e., C9D1, C11D1, C13D1, ......); Efficacy assessments will also be performed at the Safety Observation Follow-up and each EFS Follow-up.

Safety Assessment(s) All adverse events (AEs) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA). The number and incidence of treatment-emergent adverse events (TEAEs) will be summarized by system organ class and preferred term.

All the serious adverse events (SAEs) related with the study procedure will be collected from the date of the signing of informed consent form for pre-screening to the date of the signing of master informed consent form; all the SAEs will be collected from the date of the signing of master informed consent form to the date when the first dose is given; all AEs/SAEs will be collected from the date when the first dose is given to 30 days after the last dose is given, or the date when a new anti-tumor therapy is started, whichever occurs first (If HSCT is performed, safety data on and after HSCT treatment will no longer be collected; If a patient experiences disease recurrence after HSCT and is re-enrolled to receive HMPL-306 treatment, the adverse events after HSCT need to be collected); SAEs confirmed by the investigator to have a reasonable possibility of correlation with the study drug will be collected 30 days after the last dose or after the start of a new antitumor therapy, whichever occurs first.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • IDH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have signed the ICF;
  2. Be able to follow the requirements of study protocol;
  3. Age ≥18 years;
  4. (ECOG) performance status (PS) score of 0 to 2;
  5. Cohort 1: Patients with R/R primary AML harboring IDH1-R132 site mutation [WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia, with the exception of APL (AML-M3) and extramedullary recurrence of leukemia alone without bone marrow involvement]; Cohort 2: Patients with R/R primary AML harboring IDH2-R140/R172 mutations [WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia, with the exception of APL (AML-M3) and recurrence of extramedullary leukemia alone without bone marrow involvement]. A patient with both IDH1 and IDH2 mutations will be included in Cohort 2 (IDH2 mutation group);
  6. Agree to undergo bone marrow aspiration and/or before and during treatment;
  7. Be willing to complete QoL assessments at specified time points during study treatment and after treatment discontinuation;
  8. Female patients of must agree to use highly effective methods during the study and within 30 days after discontinuation of the study drug (the time limit of contraception for the chemotherapy group needs to be extended to 6 months after the last dose) (see Appendix 9 (contraception requirements) for more information), and agree not to donate eggs (oocytes) for reproductive purposes during this period; patients must not be lactating and must have a negative pregnancy test (if of childbearing potential);
  9. Male patients with female partners of childbearing potential must use condoms during intercourse and avoid donating or freezing sperm during the study and within 30 days after discontinuation of the study drug (the time limit of contraception for the chemotherapy group needs to be extended to 6 months after the last dose).
  10. Predicted survival greater than 12 weeks as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria must be excluded:

  1. Patients who received prior treatment with IDH1 inhibitors, IDH2 inhibitors, or IDH1/IDH2 dual target inhibitors;
  2. Patients with known RAS or FLT3 hotspot mutations (patients who have test results definitely switched to negative at the time of enrollment can be enrolled);

    Hotspot mutations include:

    KRAS mutations: G12 or G13 (exon 2); Q61 (exon 3) NRAS mutations: G12 or G13 (exon 2); Q61 (exon 3) FLT3 mutations: ITD; TKD (D835 or I836)

  3. Inadequate organ function, as defined below:

    • Serum total (TBIL) higher than 1.5 times the (ULN), excluding the following patients:

      - Patients with Gilbert's disease, with normal (ALT) and aspartate aminotransferase (AST), and serum TBIL ≤ 3 × ULN.

    • AST or ALT > 2.5 × ULN (if leukemia invades the liver, patients with AST and ALT levels ≤ 5 × ULN can be enrolled);
    • Estimated by Cockcroft-Gault formula \< 50 mL/min or creatinine > 1.5 × ULN;
  4. (INR) > 1.5 × ULN or activated partial thromboplastin time (aPTT) > 1.5 × ULN, except for patients who are receiving anticoagulant therapy;
  5. Blood amylase > 1.5 × ULN and assessed to be by the investigator;
  6. Current known history of liver disease, including cirrhosis, alcoholic liver disease, active infection with virus (HBV) or virus (HCV):

    • Patients who are positive for serum hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) are required to undergo HBV deoxyribonucleic acid (DNA) testing, and patients with HBV DNA test results that are either negative or below the lower limit of normal at the site can be enrolled;
    • Patients with positive HCV serology may be enrolled only if the HCV ribonucleic acid (RNA) test is negative or below the lower limit of normal at the site;
  7. Known (HIV) infection;
  8. Meet any of the following cardiac function-related criteria:

    • Any clinically significant rhythm or conduction abnormalities requiring clinical intervention;
    • Clinically significant cardiovascular diseases that require clinical intervention as judged by the investigator, including but not limited to: acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting within 6 months prior to randomization, (NYHA) Class II (inclusive) or above congestive heart failure, (LVEF) \< 45%, or uncontrolled hypertension after medication (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg);
    • Congenital long syndrome or QTcF >470 msec in females/QTcF >450 msec in males;
    • Use of drugs currently known to cause QT prolongation (Appendix 5); patients who have switched the medication by 5 half-lives of the drug prior to the dosing of the study drug or have their to be regularly monitored during the study (QTcF is required to be regularly monitored if no medication is available for replacement) could be enrolled.
  9. Patients with other primary within the last 5 years, except for patients who have been cured, and patients with the following non-invasive tumors who have been treated with definitive treatment:

    • Basal cell carcinoma of skin
    • Squamous cell carcinoma of skin and cervix
    • Carcinoma in situ of cervix
    • Breast cancer in situ
  10. Pregnant (positive pregnancy test prior to treatment) or lactating women;
  11. Patients with childbearing requirements;
  12. History of stroke or intracranial hemorrhage within 6 months prior to randomization;
  13. Patients who have undergone major surgery within 4 weeks prior to randomization;
  14. Patients who have received any monoclonal antibody for anti-tumor therapy within 3 weeks or 2 half-lives prior to randomization, whichever is longer;
  15. Patients who have received treatment with the product or investigational device in a clinical study within 3 weeks prior to randomization;
  16. Patients who have received anti-tumor treatment (chemotherapy, targeted therapy, immunotherapy, or anti-tumor vaccine, etc,) within 3 weeks prior to randomization or received radiotherapy within 3 months prior to randomization; patients who have received CAR-T therapy within 4 weeks prior to randomization; patients who have received within 60 days prior to randomization, or are receiving therapy after HSCT at screening, or are accompanied by (GVHD) requiring drug control; patients undergoing treatment for skin graft-versus-host disease (GVHD) with fixed oral doses of and/or topical may be enrolled only if they can benefit from the study treatment as assessed by the investigator; for patients receiving prophylactic intrathecal administration of chemotherapy drugs (cytarabine, dexamethasone and methotrexate) to prevent central leukemia, no is required;
  17. Central nervous system leukemia: patients with clinical symptoms suggesting active central nervous system (CNS) leukemia or confirmed CNS leukemia invasion;
  18. Patients who have received within 4 weeks prior to randomization;
  19. Use of traditional Chinese medicine with anti-tumor effect within 1 week prior to randomization;
  20. Patients with uncontrolled active systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to the infection without improvement despite appropriate antibiotic or antiviral therapy and/or other treatments), or persistent unexplained pyrexia (> 38.5℃) without improvement during the screening period (only patients with tumor fever as judged by the investigator can be enrolled);
  21. Inability to take medications orally, past surgery history or severe gastrointestinal diseases including dysphagia, active gastric ulcer, etc., which may interfere with the absorption of study drug as judged by the investigator;
  22. Insufficient compliance in participating in this clinical study as judged by the investigator;
  23. Toxicities from previous anti-tumor treatments have not yet recovered to Grade ≤ 1 (excluding alopecia);
  24. Patients with any other disease, metabolic abnormality, physical examination abnormality or clinically significant laboratory test abnormality, based on which the investigator has reason to suspect that the patient has certain disease or condition that is not suitable for treatment with the investigational product, or that will affect the interpretation of study results or will put the patient at high risk.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    HMPL-306 arm

    HMPL-306

    Drug: HMPL-306 Regimen

  • Active comparator
    Salvage treatment arm

    Salvage treatment

    Drug: Salvage Chemotherapy Regimen

Interventions

  • Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.

  • DrugSalvage Chemotherapy Regimen

    Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition: * EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5). * FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4). * LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10). * Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7).

06

What researchers measure

Primary outcomes

  1. OS

    Overall survival (OS)

    Time frame: Up to approximately 33 months

Secondary outcomes

  1. CR rate

    Proportion of patients who achieve a complete remission (CR)

    Time frame: Up to approximately 33 months

  2. CR + CRh rate

    Proportion of patients who achieve complete remission plus complete remission with partial hematologic recovery rate

    Time frame: Up to approximately 33 months

  3. CR + CRi + CRh rate

    Proportion of patients who achieve complete remission plus complete remission with incomplete hematologic recovery and partial hematologic recovery rate

    Time frame: Up to approximately 33 months

  4. Assessments for PK (pharmacokinetics)

    Maximum Plasma concentration (Cmax) of drug

    Time frame: Day1 of cycle 1, 3, 5 (each cycle is 28 days),up to approximately 33 months

  5. Assessments for PK (pharmacokinetics)

    Trough plasma concentration (Ctrough) of drug

    Time frame: Day1 of cycle 1, 3, 5 (each cycle is 28 days),up to approximately 33 months

  6. Duration of response (DOR)

    Duration of CR (DoCR), duration of CR + CRh, duration of CR + CRh + Cri

    Time frame: Up to approximately 33 months

  7. Transfusion-dependence conversion ratio

    Time frame: Up to approximately 33 months

  8. HSCT(hematopoietic stem cell transplantation) ratio

    Time frame: Up to approximately 33 months

  9. Safety(TEAE, TRAE, SAE, etc.)

    Number of participants with treatment-related adverse events, treatment-emergent adverse events, serious adverse events, adverse events leading to dose modification, adverse events leading to death as assessed by CTCAE v5.0

    Time frame: Up to approximately 33 months

  10. Quality of life (QoL)

    Quality of life (QoL), as measured by Family Reported Outcome Measure (Form-Item Health Survey)

    Time frame: Up to approximately 33 months

  11. Time to response (TTR)

    Time to first CR (TTCR), time to first CR + CRh \[TT (CR + CRh)\], time to first CR + CRh + CRi \[TT (CR + CRi + CRh)\]

    Time frame: Up to approximately 33 months

  12. EFS

    Event-free survival (EFS)

    Time frame: Up to approximately 33 months

07

Study locations

53 of 53 sites recruiting
08

References and documents

Publications

  • Hu L, Wei X, Zhao W, Hu Y, Li J, Dong Y, Gong T, Zhang X, Xu Y, Zhang Y, Xu C, Zhang C, Cai Z, Jing H, Mi R, Wu W, He W, Wang H, Tang Q, Jiang Z, Liu H, Chen G, Sun J, Chen J, Yan S, Yan H, Wangwu J, Zhong Z, Wang L, Fan S, Shi M, Su W, Huang X. HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. Med. 2025 Jun 13;6(6):100575. doi: 10.1016/j.medj.2025.100575. Epub 2025 Jan 31. PubMed 39892383 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2028, 56 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 56 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 26, 2024
StartActual
Apr 26, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Sep 30, 2029
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06387069
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Apr 26, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Aug 14, 2025

Study contacts

Erin Lou, Doctor
Contact
erinl@hutch-med.com
+86 21 2067 1942
Yu Wang, Bachelor
Contact
yuwang@hutch-med.com
(+86) 18058125909
Xiaojun Huang, Doctor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranosidenib

Start the discussion